Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: The RE-DUAL PCI trial subanalysis

The objective of this substudy was to examine the safety of switching patients with atrial fibrillation (AF) who were previously on warfarin or a direct oral anticoagulant (DOAC) to dabigatran dual therapy.

Read the full article here

Related Articles